<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04224636</url>
  </required_header>
  <id_info>
    <org_study_id>AIO-HEP-0418</org_study_id>
    <secondary_id>2019-002430-36</secondary_id>
    <nct_id>NCT04224636</nct_id>
  </id_info>
  <brief_title>Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/Bevacizumab</brief_title>
  <acronym>DEMAND</acronym>
  <official_title>A Randomized, 2-arm Non-comparative Phase II Study on the Efficacy of Atezolizumab and Roche Bevacizumab (Atezo/Bev) Followed by On-demand Selective TACE (sdTACE) Upon Detection of Disease Progression or of Initial Synchronous Treatment With TACE and Atezo/Bev on 24-months Survival Rate in the Treatment of Unresectable Hepatocellular Carcinoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of the study is to evaluate the efficacy of up-front atezolizumab/ bevacizumab&#xD;
      (Atezo/Bev) followed by on-demand selective transarterial chemoembolization (sdTACE) and of&#xD;
      initial synchronous treatment with TACE and Atezo/Bev in the treatment of unresectable HCC&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 6, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24-months survival rate</measure>
    <time_frame>24 months</time_frame>
    <description>Percentage of patients alive after 24 months since randomization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median overall survival (mOS)</measure>
    <time_frame>24 months</time_frame>
    <description>Defined as the time from treatment initiation until death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>24 months</time_frame>
    <description>Progression is defined according RECIST 1.1 and mRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>24 months</time_frame>
    <description>Response is defined by RECIST 1.1 and mRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response rate (CRR)</measure>
    <time_frame>24 months</time_frame>
    <description>Defined by the percentage of patients with disappearance of tumor manifestation at radiological evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>24 months</time_frame>
    <description>Defined as the percentage of patients who have achieved complete response, partial response and stable disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to deterioration of liver function</measure>
    <time_frame>24 months</time_frame>
    <description>Defined as time from randomization to worsening of CTCAE grade for any of these parameters: aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, albumin, and international normalized ratio (INR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to untreatable progression</measure>
    <time_frame>24 months</time_frame>
    <description>defined as time from randomization to progression not amenable to local treatment as per protocol, occurrence of vascular invasion or of extrahepatic spread, worsening of liver function to Child-Pugh score 8 or higher</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to stage-progression</measure>
    <time_frame>24 months</time_frame>
    <description>Defined as time from randomization to disease progression to BCLC C stage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first TACE (arm A)</measure>
    <time_frame>24 months</time_frame>
    <description>Defined as time from randomization to disease to the first TACE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QOL)</measure>
    <time_frame>24 months</time_frame>
    <description>Standardized assessment will be performed by using EORTC QLQ-C30 - European Organisation for Research and Treatment of Cancer - Quality of Life Core Questionnaire 30 items</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QOL)</measure>
    <time_frame>24 months</time_frame>
    <description>Standardized assessment will be performed by using EORTC QLQ-HCC18 - European Organisation for Research and Treatment of Cancer - Quality of Life Core Questionnaire - Hepatocellular carcinoma module 18</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>24 months</time_frame>
    <description>Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v5.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">106</enrollment>
  <condition>Hepatocellular Carcinoma Non-resectable</condition>
  <arm_group>
    <arm_group_label>Up-front Atezo/Bev, then TACE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive atezolizumab and bevacizumab iv every three weeks for up to 24 months. Upon detection of at least one unequivocal progressive hepatic lesion, selective TACE directed against progressive lesion(s) (sdTACE) will be performed. RFA or MWA are permitted as alternative to TACE to treat one or more lesion that cannot be reasonably selectively targeted by TACE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atezo/Bev combined with TACE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First TACE will be performed as selectively as possible against all viable tumor lesions. Atezo/Bev will be initiated within three days from TACE. Upon detection of at least one unequivocal progressive hepatic lesion, treatment with Atezo/Bev will be continued if RFA or MWA can be used to treat this/these progressive lesion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Atezolizumab Injection, Bevacizumab Injection</intervention_name>
    <description>Atezolizumab and Bevacizumab will be administered prior to or in combination with TACE</description>
    <arm_group_label>Atezo/Bev combined with TACE</arm_group_label>
    <arm_group_label>Up-front Atezo/Bev, then TACE</arm_group_label>
    <other_name>Chemoembolisation (TACE)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria&#xD;
&#xD;
          1. Patient's signed informed consent&#xD;
&#xD;
          2. Age â‰¥18 years at time of signing Informed Consent Form&#xD;
&#xD;
          3. Ability to comply with the study protocol, according to investigator's judgement&#xD;
&#xD;
          4. Life expectancy of at least 12 weeks&#xD;
&#xD;
          5. HCC with histologically confirmed diagnosis&#xD;
&#xD;
          6. Disease that is not amenable to curative surgical and/or local ablation but eligible&#xD;
             for TACE&#xD;
&#xD;
          7. ECOG Performance Status of 0 or 1&#xD;
&#xD;
          8. Child-Pugh class A or B7&#xD;
&#xD;
          9. Adequate hematologic and end-organ function&#xD;
&#xD;
         10. Negative HIV test at screening&#xD;
&#xD;
        Key Exclusion Criteria&#xD;
&#xD;
          1. Diffuse HCC or presence of vascular invasion or extrahepatic spread or more than 7&#xD;
             lesions or at least one lesion &gt;= 7 cm&#xD;
&#xD;
          2. Clinically relevant ascites&#xD;
&#xD;
          3. Uncontrolled pleural effusion or pericardial effusion&#xD;
&#xD;
          4. History or presence of hepatic encephalopathy&#xD;
&#xD;
          5. Co-infection of HBV and HCV&#xD;
&#xD;
          6. Patients on a liver transplantation list.&#xD;
&#xD;
          7. Prior systemic therapy for HCC&#xD;
&#xD;
          8. Prior treatment with TACE or selective internal radiation treatment (SIRT)&#xD;
&#xD;
          9. Any condition representing a contraindication to TACE&#xD;
&#xD;
         10. Major gastrointestinal bleeding within 4 weeks prior to randomization, untreated or&#xD;
             incompletely treated varices with bleeding or high-risk for bleeding.&#xD;
&#xD;
         11. Active or history of autoimmune disease or immune deficiency&#xD;
&#xD;
         12. Prior allogeneic stem cell or solid organ transplantation&#xD;
&#xD;
         13. History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis&#xD;
             obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of&#xD;
             active pneumonitis on screening chest computed tomography (CT) scan&#xD;
&#xD;
         14. Active tuberculosis&#xD;
&#xD;
         15. Severe infection requiring antibiotics within 4 weeks prior to randomization&#xD;
&#xD;
         16. Significant cardiovascular disease&#xD;
&#xD;
         17. History of congenital long QT syndrome or corrected QT interval &gt;500 ms at screening&#xD;
             ECG&#xD;
&#xD;
         18. Inadequately controlled arterial hypertension or prior history of hypertensive crisis&#xD;
             or hypertensive encephalopathy&#xD;
&#xD;
         19. Significant vascular disease including aortic aneurysm requiring surgical repair or&#xD;
             peripheral arterial thrombosis with 6 months prior to randomization&#xD;
&#xD;
         20. History of abdominal or tracheoesophageal fistula or gastrointestinal perforation, or&#xD;
             intra-abdominal abscess within 6 months prior to randomization.&#xD;
&#xD;
         21. History or clinical signs of gastrointestinal obstruction or requirement for routine&#xD;
             parenteral hydration, parenteral nutrition, or tube feeding. Evidence of abdominal&#xD;
             free air that is not explained by paracentesis or recent surgical procedure&#xD;
&#xD;
         22. History of intra-abdominal inflammatory process within 6 months prior to&#xD;
             randomization, including but not limited to peptic ulcer disease, diverticulitis, or&#xD;
             colitis&#xD;
&#xD;
         23. Evidence of bleeding diathesis or significant coagulopathy&#xD;
&#xD;
         24. Any other disease, metabolic dysfunction, physical examination finding, or clinical&#xD;
             laboratory finding that contraindicates the use of an investigational drug, may affect&#xD;
             the interpretation of the results, or may render the patient at high risk from&#xD;
             treatment complications.&#xD;
&#xD;
         25. Uncontrolled tumor-related pain. Patients requiring pain medication must be on a&#xD;
             stable regimen at enrollment.&#xD;
&#xD;
         26. Severe, non healing or dehisced wound, active ulcer, or untreated bone fracture&#xD;
&#xD;
         27. History of malignancy other than HCC, with the exception of patients who have been&#xD;
             disease-free for at least five years before enrollment or patients with adequately&#xD;
             treated and completely resected basal cell or squamous cell skin cancer, in situ&#xD;
             cervical, breast or prostate cancer, stage I uterine cancer&#xD;
&#xD;
         28. Current or recent (within 10 days of randomization) use of acetylsalicyclic acid or&#xD;
             treatment with dipyramidole, ticlopidine, clopidogrel, and cilostazol&#xD;
&#xD;
         29. Current or recent (within 10 days prior to randomization) use of full dose oral or&#xD;
             parenteral anticoagulants or thrombolytic agents for therapeutic purpose.&#xD;
&#xD;
         30. Chronic daily treatment with a nonsteroidal anti-inflammatory drug (NSAID). Occasional&#xD;
             use of NSAIDs for the symptomatic relief of medical conditions such as headache or&#xD;
             fever is allowed.&#xD;
&#xD;
         31. Treatment with a live, attenuated vaccine within 4 weeks prior to randomization, or&#xD;
             anticipation of need for such a vaccine during atezolizumab treatment or within 5&#xD;
             months after the last dose of atezolizumab&#xD;
&#xD;
         32. Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including&#xD;
             anti-CTLA-4, anti-PD-1, and antiPD-L1 therapeutic antibodies&#xD;
&#xD;
         33. Hypersensitivity to atezolizumab or bevacizumab or any of the excipients, known&#xD;
             hypersensitivity to Chinese hamster ovary cell products, known hypersensitivity to&#xD;
             human or humanized antibodies&#xD;
&#xD;
         34. Treatment with systemic immunostimulatory agents (including, but not limited to,&#xD;
             interferon and interleukin 2 [IL-2]) within 4 weeks or 5 half-lives of the drug&#xD;
             (whichever is longer) prior to randomization&#xD;
&#xD;
         35. Treatment with systemic immunosuppressive medication within 2 weeks prior to&#xD;
             randomization, or anticipation of need for systemic immunosuppressive medication&#xD;
             during study treatment, with the following exceptions:&#xD;
&#xD;
             Patients who received acute, low-dose systemic immunosuppressant medication or a&#xD;
             one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of&#xD;
             corticosteroids for a contrast allergy) are eligible.&#xD;
&#xD;
             Inhaled corticosteroids for chronic obstructive pulmonary disease or bronchial asthma,&#xD;
             supplemental mineralocorticosteroids or low-dose corticosteroids for adrenalcortical&#xD;
             insufficiency are allowed.&#xD;
&#xD;
         36. Major surgical procedure other than for diagnosis, open biopsy, or significant&#xD;
             traumatic injury within 28 days prior to randomization, or abdominal surgery,&#xD;
             abdominal interventions or significant abdominal traumatic injury within 60 days prior&#xD;
             to randomization or anticipation of need for major surgical procedure during the&#xD;
             course of the study or non-recovery from side effects of any such procedure&#xD;
&#xD;
         37. Core biopsy or other minor surgical procedure, excluding placement of a vascular&#xD;
             access device, within 3 days prior to the first dose of bevacizumab&#xD;
&#xD;
         38. Pregnant or breastfeeding females&#xD;
&#xD;
         39. Participation in a clinical trial or experimental drug treatment within 28 days prior&#xD;
             to inclusion in the clinical trial or within a period of 5 half-lives of the&#xD;
             substances administered in a clinical trial or during an experimental drug treatment&#xD;
             prior to inclusion in the clinical trial, depending on which period is longest, or&#xD;
             simultaneous participation in another clinical trial while taking part in this&#xD;
             clinical trial.&#xD;
&#xD;
         40. Patient committed to an institution by virtue of an order issued either by the&#xD;
             judicial or the administrative authorities&#xD;
&#xD;
         41. Patient possibly dependent from the investigator including the spouse, children and&#xD;
             close relatives of any investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Najib Ben Khaled, MD</last_name>
    <phone>+49 89 4400 78160</phone>
    <email>najib.benkhaled@med.uni-muenchen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>KEM Evang. Kliniken Essen Mitte</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pluntke Stefan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Jena</name>
      <address>
        <city>Jena</city>
        <zip>07743</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philipp Reuken, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Cologne</name>
      <address>
        <city>KÃ¶ln</city>
        <zip>50931</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dirk Waldschmidt, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Munich</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrico N De Toni, MD</last_name>
      <phone>+49 (0)894400-0</phone>
      <email>enrico.detoni@med.uni-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Enrico N De Toni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jens Ricke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julia Mayerle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Rechts der Isar of the Technical University Munich</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ursula Ehmer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arne Kandulski, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital TÃ¼bingen</name>
      <address>
        <city>TÃ¼bingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Bitzer, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://demand-study.com/</url>
    <description>https://demand-study.com/</description>
  </link>
  <link>
    <url>https://demand-study.de/</url>
    <description>https://demand-study.de/</description>
  </link>
  <reference>
    <citation>De Toni EN. Immune checkpoint inhibitors: use them early, combined and instead of TACE? Gut. 2020 Oct;69(10):1887-1888. doi: 10.1136/gutjnl-2019-319658. Epub 2019 Oct 14.</citation>
    <PMID>31611301</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>December 19, 2019</study_first_submitted>
  <study_first_submitted_qc>January 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>October 22, 2020</last_update_submitted>
  <last_update_submitted_qc>October 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>Enrico De Toni</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

